http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106383231-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2016-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106383231-B |
| titleOfInvention | Marker combination for diagnosing liver cancer and application thereof |
| abstract | The invention relates to a marker combination for detecting liver cancer stage and application thereof. Specifically, the invention provides application of syndecan-1 and sphingosine-1-phosphate in preparing a diagnostic kit for detecting liver cancer stages. Research shows that the expression level of syndecan-1 and sphingosine-1-phosphate in the serum of liver cancer patients is obviously higher than that of normal healthy people, the expression level of syndecan-1 and sphingosine-1-phosphate in the serum of liver cancer patients is positively correlated, and the expression levels of different stage patients are obviously different. Therefore, the combination of syndecan-1 and sphingosine-1-phosphate can be used as a marker for liver cancer stage diagnosis (especially serological diagnosis), and a corresponding detection method and a corresponding kit can be provided by utilizing the combination to realize the stage detection of the liver cancer. |
| priorityDate | 2016-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.